Targeted Mesoporous Silica Nanoparticles (MSNs) for Theranostic Applications
A special issue of Future Pharmacology (ISSN 2673-9879).
Deadline for manuscript submissions: 30 September 2025 | Viewed by 114
Special Issue Editor
Special Issue Information
Dear Colleagues,
Mesoporous silica nanoparticles (MSNs) provide a versatile drug delivery system with notable benefits in drug absorption, distribution, mechanism of action, and precision targeting. They have emerged as a valuable platform for various disease theranostics due to their distinctive features, including a large surface area, adjustable synthesis conditions, easy functionalization, and exceptional biocompatibility. MSNs enhance the solubility and bioavailability of hydrophobic drugs; however, gastrointestinal absorption remains a challenge. Intravenous administration is the one of the most preferred approaches for fast systemic circulation. They also facilitate drug uptake in respiratory and central nervous system disorders due to their high permeability. Additionally, MSNs can be engineered for imaging applications, allowing for the simultaneous diagnosis and treatment (theranostics) of various diseases, including cancer, infectious diseases, and neurodegenerative disorders. Also, there have been ongoing advancements in MSNs for biosensing and tissue engineering applications, as well as a progressive transition from fundamental research to clinical trials. However, MSNs may generate reactive oxygen species, leading to cytotoxicity, and further bare MSNs can disrupt red blood cells and induce clotting, thus surface modifications are required. Also, the inappropriate clearance of large MSNs may lead to liver or spleen toxicity. Thus, although preclinical findings are promising, additional research is required to refine safety, effectiveness, and regulatory compliance for clinical use.
This Special Issue aims to provide an in-depth analysis of the latest advances in mesoporous silica nanoparticle (MSN)-based nanocarriers for improved theranostic applications. This Special Issue welcomes original research articles and reviews focused on (but not limited to) the following research areas:
- MSNs and functionalized MSNs;
- Targeted drug delivery;
- Antimicrobial and anticancer therapies;
- Neurodegenerative diseases;
- Immunotherapy;
- Phototherapy;
- Chemotherapy;
- Pharmacological and molecular mechanisms;
- Pharmacokinetics and biodistribution studies;
- Clinical and preclinical studies;
- Toxicological studies.
Dr. Sabya Sachi Das
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MSNs and functionalized MSNs
- antimicrobial and anticancer therapies
- immunotherapy
- phototherapy
- chemotherapy
- pharmacological and molecular mechanisms
- pharmacokinetics and biodistribution studies
- clinical and preclinical studies
- toxicological studies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
